GlassScriptPhysician profile
Jeffrey English
NPI 1508856790
$749,321.01
in general payments reported to CMS, 2019-2025
46 companies · $74K in 2025
The $74K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187K · 2020: $74K · 2021: $88K · 2022: $118K · 2023: $106K · 2024: $101K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $207K · Consulting Fee: $30K · Travel and Lodging: $15K · Food and Beverage: $15K · Honoraria: $14K · Education: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $207,476.00 |
| Consulting Fee | $29,783.00 |
| Travel and Lodging | $15,262.43 |
| Food and Beverage | $14,738.34 |
| Honoraria | $14,425.00 |
| Education | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $259,221.26 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Emd Serono, INC. | $256,446.75 | 2019-2025 | Mavenclad, Mavenclad |
| Genzyme Corporation | $68,846.16 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $62,283.68 | 2020-2025 | Zeposia |
| Celgene Corporation | $29,443.24 | 2019-2025 | Zeposia |
| Horizon Therapeutics Plc | $21,237.32 | 2021-2023 | Uplizna |
| Amgen INC. | $19,647.73 | 2023-2025 | Uplizna, Aimovig |
| Genentech USA, INC. | $18,284.41 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $4,469.24 | 2023-2025 | |
| Abbvie INC. | $3,150.05 | 2021-2025 | |
| Genentech, INC. | $2,603.07 | 2020-2025 | Ocrevus |
| Novartis Pharmaceuticals Corporation | $833.67 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $465.33 | 2019-2024 | Ultomiris |
| Pfizer INC. | $292.79 | 2023-2025 | |
| Argenx US, INC. | $259.97 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $226.81 | 2022-2025 | Nuplazid |
| Eisai INC. | $181.65 | 2024-2025 | |
| Lilly USA, LLC | $147.05 | 2023-2025 | Kisunla, Emgality |
| Boston Scientific Corporation | $143.14 | 2021-2025 | Bodyguardian |
| Sk Life Science, INC. | $124.66 | 2021 | |
| Axsome Therapeutics, INC. | $112.31 | 2024-2025 | Sunosi |
| Amneal Pharmaceuticals LLC | $104.03 | 2023-2025 | Rytary, Lyvispah, Ongentys |
| Neurocrine Biosciences, INC. | $93.44 | 2023-2025 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $84.71 | 2019 | |
| Neurelis, INC. | $72.01 | 2023 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $59.48 | 2023-2024 | Austedo Xr |
| Ucb, INC. | $51.53 | 2021-2024 | Rystiggo |
| Lundbeck LLC | $49.27 | 2024-2025 | Rexulti, Vyepti |
| Ethicon US, LLC | $46.64 | 2025 | Surgiflo Hemostatic Matrix, Surgicel Nu-Knit, Vistaseal |
| Mdd US Operations, LLC | $44.04 | 2024 | Gocovri |
| Astrazeneca Pharmaceuticals LP | $38.56 | 2023-2025 | Wainua, Flumist Quadrivalent |
| Livanova USA, INC. | $35.87 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Alnylam Pharmaceuticals INC. | $27.63 | 2024 | Amvuttra |
| Invivyd INC | $27.19 | 2025 | Pemgarda |
| Ani Pharmaceuticals, INC. | $25.33 | 2022 | |
| Harmony Biosciences LLC | $25.28 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.23 | 2022 | |
| Cycle Pharmaceuticals INC | $20.52 | 2024 | Tascenso Odt |
| Jazz Pharmaceuticals INC. | $20.04 | 2022 | |
| Mallinckrodt Hospital Products INC. | $19.95 | 2023 | Acthar |
| Banner Life Sciences, LLC | $17.52 | 2024 | |
| Greenwich Biosciences, INC. | $14.45 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey English listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.